Brian Holmes is the first man in the UK and only the fifth in the world to take part in the clinical trial A prostate cancer ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

They use the body's own immune system to detect and kill cancer cells "Immunotherapies have been very promising and has ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...